Top
Leukocyte adhesion deficiency type 1 - Healing Genes
1242
post-template-default,single,single-post,postid-1242,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Leukocyte adhesion deficiency type 1

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I): A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector Encoding the ITGB2 Gene


Phase 1 / 2

DESCRIPTION:

Doctors at the University of California, Los Angeles seek patients with severe Leukocyte Adhesion Deficiency-I (LAD-I) to trial a therapeutic gene therapy. This therapy utilizes the patient’s own (autologous) stem cells, which will be gene-modified in the lab to impart a gene for the CD18 immune cell receptor that is lacking in the LAD-I disease. They hope the gene will express the receptor after gene modification and improve the symptoms of the disease. Prior to the modified cells being re-administered via IV, the patient will receive chemotherapy.

Survival and improvement in the patients will be followed for 2 years.


PATIENT MUST:

  • Be 3 months of age or older
  • Have confirmed diagnosis of severe LAD-I meeting the study’s clinical criteria
  • Not have a medically-eligible human leukocyte antigen (HLA)-identical sibling donor transplant.

THE STUDY INVOLVES:

  1. Screening to confirm acceptance to the study.
  2. Blood draw to recover the patient’s own stem cells, which will be gene-modified in the lab (no treatment during that period).
  3. Admission to the study center and a course of chemotherapy.
  4. Single infusion of gene-modified stem cells, with close observation, before the final dose of chemotherapy.
  5. Follow up will continue for 2 years.

LOCATIONS & CONTACTS:

The trial will take place at the University of California, Los Angeles. Map.

Contact:
Donald B Kohn, MD  |  310-794-1964  |  [email protected]

SPONSORS:
Rocket Pharmaceuticals Inc.

Or go online:
https://clinicaltrials.gov/ct2/show/NCT03812263

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader